# US 6,730,319 B2 · Pharmaceutical compositions having depressed melting points

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,319 B2
- Document ID: US6730319B2
- Status: Granted
- Kind: B2
- Application number: 10/154,554
- Filed: 2002-05-23
- Published: 2003-02-27
- Granted: 2004-05-04
- Earliest claimed: 2001-06-06
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Karsten Maeder; Lukas Christoph Scheibler; Hans Steffen
- Web page: https://patentgrep.com/patent/US6730319B2

## CPC

- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/145: {with organic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 31/365: Lactones
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions that contain a solid pharmaceutically active compound having a melting point ≧37° C. and a fatty acid or a fatty acid salt or a mixture of a fatty acid and a fatty acid salt. Such composition results in a depression in melting point to ≦37° C. upon contact with an aqueous solution thereby providing an improved outlook for absorption.

## Claims

### Claim 1

A solid pharmaceutical composition, which comprises:
a) a solid pharmaceutically active compound that is a lipase inhibitor and has a melting point ≧37° C., and
b) a fatty acid or a fatty acid salt or a mixture of a fatty acid and a fatty acid salt;
the pharmaceutically active compound and the fatty acid or a fatty acid salt or a mixture of a fatty acid and a fatty acid salt being present in amounts such that when the composition is contacted with an aqueous solution having a pH value ≦8, the melting point of the composition is less than the melting point of the solid pharmaceutically active compound and ≦37° C.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the pharmaceutically active compound is orlistat.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the aqueous solution is buccal or gastric fluid.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is selected from the group consisting of C8 to C24 saturated and non-saturated fatty acids, salts of C8 to C24 saturated and non-saturated fatty acids, dicarboxylic acids, and salts of dicarboxylic acids.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the fatty acid is a C12 to C18 saturated fatty acid or a salt of C12 to C18 saturated fatty acid.

### Claim 6 (depends on 4)

The composition according to claim 4, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is selected form the group consisting of lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid and behenic acid, and salts thereof.

### Claim 7 (depends on 6)

The composition according to claim 6, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is selected form the group consisting of lauric acid, myristic acid, and palmitic, and salts thereof.

### Claim 8 (depends on 7)

The composition according to claim 7, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is selected from the group consisting or lauric acid, myristic acid, and salts thereof.

### Claim 9 (depends on 4)

The composition according to claim 4, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is selected from the group consisting of C12 to C18 mono- or polyunsaturated fatty acid and salts thereof.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is selected from the group consisting of palmitoleic acid, oleic acid, elaidic acid, erucic acid, linoleic acid, gamma-linolenic acid, alpha-linolenic acid and arachidonic acid, and salts thereof.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is selected from the group consisting of oleic acid or linoleic acid and salts thereof.

### Claim 12 (depends on 4)

The composition according to claim 4, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is a C5 to C24 dicarboxylic acid or salt thereof.

### Claim 13 (depends on 4)

The composition according to claim 4, wherein the fatty acid or the fatty acid salt or the mixture of a fatty acid and a fatty acid salt is selected from the group consisting of glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, dodecanedioc acid, and tetradecandioic acid, and salts thereof.

### Claim 14 (depends on 1)

The composition according to claim 1, wherein the fatty acid or the fatty acid salt is a mixture of two or more fatty acids or two or more fatty acid salts.

### Claim 15 (depends on 1)

The composition according to claim 1, wherein the fatty acid salt is a ammonium, bis(2-hydroxyethyl)ammonium, diethanolammonium, triethanolammonium, sodium, potassium, magnesium or calcium salt.

### Claim 16 (depends on 15)

The composition according to claim 15, wherein the fatty acid salt is a sodium or potassium salt.

### Claim 17 (depends on 1)

The composition according to claim 1, wherein 0.05 mg to 20 mg fatty acid or 0.05 mg to 20 mg fatty acid salt or 0.05 mg to 20 mg of a mixture of a fatty acid and fatty acid salt is used per 1 mg pharmaceutically active compound.

### Claim 18 (depends on 17)

The composition according to claim 17, wherein 0.5 mg to 2 mg fatty acid or 0.5 mg to 2 mg fatty acid salt or 0.5 to 2 mg of a mixture of a fatty acid and fatty acid salt is used per 1 mg pharmaceutically active compound.

### Claim 19 (depends on 2)

The composition according to claim 2, wherein the orlistat is present in an amount of 10 to 240 mg.

### Claim 20 (depends on 19)

The composition according to claim 19, wherein the orlistat is present in an amount of 30 to 120 mg.

### Claim 21 (depends on 20)

The composition according to claim 20, wherein the orlistat is present in an amount of 40, 60, 80, 100, or 120 mg.

### Claim 22 (depends on 20)

The composition according to claim 20, wherein the orlistat is present in an amount of 60 to 120 mg and the fatty acid or fatty acid salt or a mixture of a fatty acid and a fatty acid salt is present in the amount of 20 mg to 100 mg.

### Claim 23 (depends on 22)

The composition according to claim 22, wherein the orlistat is present in an amount of 120 mg orlistat and the fatty acid or fatty acid salt or a mixture of a fatty acid and a fatty acid salt is present in the amount of 60 mg.

### Claim 24 (depends on 1)

The composition according to claim 1 further comprising one or more pharmaceutically acceptable excipients.

### Claim 25 (depends on 24)

The composition according to claim 24, wherein the one or more pharmaceutically acceptable excipients are selected from the group consisting of mannitol, lactose, HPMC, talcum, sorbitol, polyvinylpyrrolidone, lecithin, trimyristine, polyethylenglycol, sucrose ester, polysorbate, polyoxethylenstearate, and dimethicon.

### Claim 26 (depends on 25)

The composition according to claim 25, wherein the one or more pharmaceutically acceptable excipients are selected from the group consisting of sucrose ester and lactose.

### Claim 27 (depends on 26)

The composition according to claim 26, wherein the composition comprises 10-240 mg of orlistat, 0.5-2000 mg of a fatty acid or a fatty acid salt or a mixture of a fatty acid and a fatty acid salt, 5-200 mg of sucrosepalmitate.

### Claim 28 (depends on 27)

The composition according to claim 27 further comprising 1.5 g lactose.
